Beur schreef op 10 april 2016 22:09:
Valeant CEO Pearson may be held in contempt Apr 10 2016, 08:18 ET | By: Yoel Minkoff, SA News Editor
More trouble at Valeant Pharmaceuticals (NYSE:VRX)... A Senate committee may soon start contempt proceedings against the drugmaker's chief executive.
"Michael Pearson was under subpoena to appear for a deposition today related to the Senate Special Committee on Aging's drug pricing investigation, and he did not comply with that subpoena," Senators Susan Collins and Claire McCaskill said late Friday. "It is our intent to initiate contempt proceedings against him."